Product
TLC599
Aliases
12 mg DSP with 100 µmol PL (1.0 mL), TLC599 Injection, TLC599 LD group
2 clinical trials
1 indication
Indication
Osteoarthritis of the KneeClinical trial
A Phase 2, Open-label, Pharmacokinetic Study of a Single Intra-articular Administration of TLC599 in Subjects With Mild to Moderate Osteoarthritis of the KneeStatus: Completed, Estimated PCD: 2023-11-07
Clinical trial
A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of KneeStatus: Completed, Estimated PCD: 2018-07-04